
Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030
Description
Plasma Fractionation Market by Product (Albumin, Coagulation Factor Concentrates, Immunoglobulin), Application (Critical Care, Hemato-Oncology, Hematology), End-User - Global Forecast 2024-2030
The Plasma Fractionation Market size was estimated at USD 35.52 billion in 2023 and expected to reach USD 38.95 billion in 2024, at a CAGR 10.45% to reach USD 71.27 billion by 2030.
Global Plasma Fractionation Market
Plasma fractionation refers to collecting, separating, and purifying various essential components present in human plasma, primarily including albumin, immunoglobulins, coagulation factors, and other proteins. These components have many applications in medical treatments, such as hemophilia therapy, immunity disorders treatment, wound healing support, neurology therapy, and other rare diseases. The demand for source plasma has been steadily increasing due to its role as a vital ingredient in several life-saving therapies. This surge can be attributed to an aging population prone to chronic illnesses requiring blood-based therapies and the rising prevalence of immune disorders. In addition, rising awareness about blood-related diseases among patients contributes significantly to this market's expansion. However, stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies may hamper the market demand. New advancements in production technology further boost opportunities for the players involved in this field. Moreover, strategic collaborations among various stakeholders drive innovative research work within the industry that provides novel solutions and is expected to create a lucrative market opportunity in the forecasted period.
Regional Insights
The Americas has a significant market presence in the plasma fractionation market due to a well-established healthcare infrastructure, high prevalence of immunodeficiency diseases, and an increasing geriatric population. In Europe, EU countries have a strong regulatory framework governing the plasma fractionation industry. The European Medicines Agency (EMA) regulates manufacturing practices and oversees quality standards for blood-derived products, significantly driving the region's market demand. The MEA region presents lucrative opportunities due to rising incomes and expanding access to healthcare services. The Asia-Pacific observed a developing landscape in the plasma fractionation market owing to rapid urbanization and economic development that is driving investments in healthcare infrastructure. Additionally, there is an increasing focus on blood safety regulations by governments in the APAC region, presenting opportunities for market players.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Plasma Fractionation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Plasma Fractionation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.
Market Segmentation & Coverage
This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:
Product
Albumin
Coagulation Factor Concentrates
Factor IX
Factor VIII
Factor XIII
Fibrinogen Concentrates
Prothrombin Complex Concentrate
Von Willebrand Factor
Immunoglobulin
Intravenous Immunoglobulin
Subcutaneous Immunoglobulin
Protease Inhibitors
Application
Critical Care
Hemato-Oncology
Hematology
Neurology
Pulmonology
Rheumatology
End-User
Academic & Research Institutes
Clinical Research Laboratories
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Plasma Fractionation Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Plasma Fractionation Market?
3. What are the technology trends and regulatory frameworks in the Plasma Fractionation Market?
4. What is the market share of the leading vendors in the Plasma Fractionation Market?
5. Which modes and strategic moves are suitable for entering the Plasma Fractionation Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
182 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Plasma Fractionation Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
- 5.1.1.2. Government initiatives to increase plasma collection
- 5.1.1.3. Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities
- 5.1.2. Restraints
- 5.1.2.1. Presence of new pathogenic agents that resist the present viral inactivation treatments
- 5.1.3. Opportunities
- 5.1.3.1. Continuous advancements in process development technology for improved formulations
- 5.1.3.2. Exponential utilization in new clinical trials and growing R&D activities in plasma treatment
- 5.1.4. Challenges
- 5.1.4.1. Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies
- 5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising use of plasma fractionation for immunoglobulins purification
- 5.2.2. Application: Proliferating use to treat hematological disorders
- 5.2.3. End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Plasma Fractionation Market, by Product
- 6.1. Introduction
- 6.2. Albumin
- 6.3. Coagulation Factor Concentrates
- 6.4.1. Factor IX
- 6.4.2. Factor VIII
- 6.4.3. Factor XIII
- 6.4.4. Fibrinogen Concentrates
- 6.4.5. Prothrombin Complex Concentrate
- 6.4.6. Von Willebrand Factor
- 6.4. Immunoglobulin
- 6.5.1. Intravenous Immunoglobulin
- 6.5.2. Subcutaneous Immunoglobulin
- 6.5. Protease Inhibitors
- 7. Plasma Fractionation Market, by Application
- 7.1. Introduction
- 7.2. Critical Care
- 7.3. Hemato-Oncology
- 7.4. Hematology
- 7.5. Neurology
- 7.6. Pulmonology
- 7.7. Rheumatology
- 8. Plasma Fractionation Market, by End-User
- 8.1. Introduction
- 8.2. Academic & Research Institutes
- 8.3. Clinical Research Laboratories
- 9. Americas Plasma Fractionation Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Plasma Fractionation Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Plasma Fractionation Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Agreement, Collaboration, & Partnership
- 12.3.1.1. Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations
- 12.3.2. New Product Launch & Enhancement
- 12.3.2.1. Kedrion presented at plasma fractionation workshop in Saudi Arabia
- 12.3.3. Award, Recognition, & Expansion
- 12.3.3.1. CSL's USD470 Million Plasma Fractionation Facility Opens in Marburg, Germany
- 12.3.3.2. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. 3M Company
- 13.1.2. ADMA Biologics, Inc.
- 13.1.3. Bharat Serums and Vaccines Limited
- 13.1.4. Bio Products Laboratory Ltd.
- 13.1.5. Biotest AG by Grifols, S.A.
- 13.1.6. China Biologic Products, Inc.
- 13.1.7. CSL Limited
- 13.1.8. Emergent BioSolutions Inc.
- 13.1.9. Fusion Health Care Pvt. Ltd.
- 13.1.10. GC Biopharma corp.
- 13.1.11. Grifols, S.A.
- 13.1.12. HEINKEL Process Technology GmbH
- 13.1.13. Hemarus Therapeutics Ltd
- 13.1.14. Intas Pharmaceuticals Ltd.
- 13.1.15. Kamada Ltd.
- 13.1.16. Kedrion S.p.A.
- 13.1.17. LFB SA
- 13.1.18. Merck KGaA
- 13.1.19. Octapharma AG
- 13.1.20. PlasmaGen BioSciences Pvt. Ltd.
- 13.1.21. Prothya Biosolutions B.V.
- 13.1.22. Sanquin
- 13.1.23. Shanghai Raas Blood Products Co. Ltd
- 13.1.24. SK Plasma Co.,Ltd.
- 13.1.25. STERIS plc
- 13.1.26. Takeda Pharmaceutical Company Ltd
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. PLASMA FRACTIONATION MARKET RESEARCH PROCESS
- FIGURE 2. PLASMA FRACTIONATION MARKET SIZE, 2023 VS 2030
- FIGURE 3. PLASMA FRACTIONATION MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. PLASMA FRACTIONATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. PLASMA FRACTIONATION MARKET DYNAMICS
- FIGURE 7. PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
- FIGURE 8. PLASMA FRACTIONATION MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 10. PLASMA FRACTIONATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 12. PLASMA FRACTIONATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES PLASMA FRACTIONATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PLASMA FRACTIONATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. PLASMA FRACTIONATION MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. PLASMA FRACTIONATION MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.